Literature DB >> 29564182

Updates on immunotherapy for colorectal cancer.

Aparna Kalyan1,2, Sheetal Kircher2, Hiral Shah1,2, Mary Mulcahy2, Al Benson2.   

Abstract

Despite significant advances in standard of care therapies, the 5-year survival rate for metastatic colorectal cancer (CRC) remains around 12%. Immunotherapy has not provided the stellar advances in colorectal cancer that has been seen in other malignancies. Immunotherapy appears to play a pivotal role in microsatellite unstable CRC tumors where the response rates are profound. These results have led to FDA approval of pembrolizumab for MSI-H CRC tumors. Additional research into several new immune agents including IDO inhibitors, vaccine therapy and combinatorial agents are being evaluated for CRC. This review will provide an overview of the approaches currently being investigated.

Entities:  

Keywords:  Colorectal cancer (CRC); immunotherapy; microsatellite instability (MSI); vaccine therapy

Year:  2018        PMID： 29564182      PMCID： PMC5848033          DOI： 10.21037/jgo.2018.01.17

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN： 2078-6891


  78 in total

Review 1.  Rational Peptide-based vaccine design for cancer immunotherapeutic applications.

Authors:  E Lazoura; V Apostolopoulos
Journal:  Curr Med Chem       Date:  2005       Impact factor: 4.530

2.  Signals from OX40 regulate nuclear factor of activated T cells c1 and T cell helper 2 lineage commitment.

Authors:  Takanori So; Jianxun Song; Katsuji Sugie; Amnon Altman; Michael Croft
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-24       Impact factor: 11.205

3.  Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207).

Authors:  D A Kooby; J F Carew; M W Halterman; J E Mack; J R Bertino; L H Blumgart; H J Federoff; Y Fong
Journal:  FASEB J       Date:  1999-08       Impact factor: 5.191

Review 4.  Tryptophan and the immune response.

Authors:  John R Moffett; Ma Aryan Namboodiri
Journal:  Immunol Cell Biol       Date:  2003-08       Impact factor: 5.126

5.  MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study.

Authors:  Takashi Kimura; John R McKolanis; Lynda A Dzubinski; Kazi Islam; Douglas M Potter; Andres M Salazar; Robert E Schoen; Olivera J Finn
Journal:  Cancer Prev Res (Phila)       Date:  2012-12-17

6.  Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase.

Authors:  Catherine Uyttenhove; Luc Pilotte; Ivan Théate; Vincent Stroobant; Didier Colau; Nicolas Parmentier; Thierry Boon; Benoît J Van den Eynde
Journal:  Nat Med       Date:  2003-09-21       Impact factor: 53.440

7.  Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells.

Authors:  Gerald Brandacher; Alexander Perathoner; Ruth Ladurner; Stefan Schneeberger; Peter Obrist; Christiana Winkler; Ernst R Werner; Gabriele Werner-Felmayer; Helmut G Weiss; Georg Göbel; Raimund Margreiter; Alfred Königsrainer; Dietmar Fuchs; Albert Amberger
Journal:  Clin Cancer Res       Date:  2006-02-15       Impact factor: 12.531

8.  Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion.

Authors:  Roch Houot; Matthew J Goldstein; Holbrook E Kohrt; June H Myklebust; Ash A Alizadeh; Jack T Lin; Jonathan M Irish; James A Torchia; Arne Kolstad; Lieping Chen; Ronald Levy
Journal:  Blood       Date:  2009-07-29       Impact factor: 22.113

9.  PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer.

Authors:  Zhiqiang Guo; Xin Wang; Dali Cheng; Zhijun Xia; Meng Luan; Shulan Zhang
Journal:  PLoS One       Date:  2014-02-27       Impact factor: 3.240

10.  A phase I study of indoximod in patients with advanced malignancies.

Authors:  Hatem H Soliman; Susan E Minton; Hyo Sook Han; Roohi Ismail-Khan; Anthony Neuger; Fatema Khambati; David Noyes; Richard Lush; Alberto A Chiappori; John D Roberts; Charles Link; Nicholas N Vahanian; Mario Mautino; Howard Streicher; Daniel M Sullivan; Scott J Antonia
Journal:  Oncotarget       Date:  2016-04-19
View more
  57 in total

1.  Innovating Cancer Care Delivery: the Example of the 4R Oncology Model for Colorectal Cancer Patients.

Authors:  Julia Trosman; Christine Weldon; Sheetal Kircher; William Gradishar; Al Benson
Journal:  Curr Treat Options Oncol       Date:  2019-02-11

2.  The Novel Small-Molecule SR18662 Efficiently Inhibits the Growth of Colorectal Cancer In Vitro and In Vivo.

Authors:  Julie Kim; Chao Wang; Ainara Ruiz de Sabando; Hannah L Cole; Timothy J Huang; Jie Yang; Thomas D Bannister; Vincent W Yang; Agnieszka B Bialkowska
Journal:  Mol Cancer Ther       Date:  2019-07-29       Impact factor: 6.261

3.  Personalised mapping of tumour development in synchronous colorectal cancer patients.

Authors:  Valentina Thomas; Maura B Cotter; Miriam Tosetto; Yi Ling Khaw; Robert Geraghty; Desmond C Winter; Elizabeth J Ryan; Kieran Sheahan; Simon J Furney
Journal:  NPJ Genom Med       Date:  2020-07-03       Impact factor: 8.617

Review 4.  Comprehensive review of targeted therapy for colorectal cancer.

Authors:  Yuan-Hong Xie; Ying-Xuan Chen; Jing-Yuan Fang
Journal:  Signal Transduct Target Ther       Date:  2020-03-20

5.  Evaluating Mismatch Repair/Microsatellite Instability Status Using Cytology Effusion Specimens to Determine Eligibility for Immunotherapy.

Authors:  Elizabeth M Jacobi; Gene Landon; Russell R Broaddus; Sinchita Roy-Chowdhuri
Journal:  Arch Pathol Lab Med       Date:  2020-03-30       Impact factor: 5.534

6.  Genomics: the power, potential and pitfalls of the new technologies and how they are transforming healthcare.

Authors:  Katherine S Josephs; Alison Berner; Angela George; Richard H Scott; Helen V Firth; Katrina Tatton-Brown
Journal:  Clin Med (Lond)       Date:  2019-07       Impact factor: 2.659

7.  Protein tyrosine phosphatase nonreceptor type 2 controls colorectal cancer development.

Authors:  Egle Katkeviciute; Larissa Hering; Ana Montalban-Arques; Philipp Busenhart; Marlene Schwarzfischer; Roberto Manzini; Javier Conde; Kirstin Atrott; Silvia Lang; Gerhard Rogler; Elisabeth Naschberger; Vera S Schellerer; Michael Stürzl; Andreas Rickenbacher; Matthias Turina; Achim Weber; Sebastian Leibl; Gabriel E Leventhal; Mitchell Levesque; Onur Boyman; Michael Scharl; Marianne R Spalinger
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

8.  Molecular Oncology in Management of Colorectal Cancer.

Authors:  Ramraj Nagendra Gupta Vemala; Sanjeev Vasudev Katti; Bhawna Sirohi; Divya Manikandan; Govind Nandakumar
Journal:  Indian J Surg Oncol       Date:  2021-03-16

Review 9.  Insights into the therapeutic potential of histone deacetylase inhibitor/immunotherapy combination regimens in solid tumors.

Authors:  Nada K Sedky; Alyaa A Hamdan; Salma Emad; Aya L Allam; Mohamed Ali; Mai F Tolba
Journal:  Clin Transl Oncol       Date:  2022-01-23       Impact factor: 3.405

Review 10.  Combining therapeutic vaccines with chemo- and immunotherapies in the treatment of cancer.

Authors:  Matthew D Kerr; David A McBride; Arun K Chumber; Nisarg J Shah
Journal:  Expert Opin Drug Discov       Date:  2020-08-31       Impact factor: 6.098
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.